TP53 and neoplasm: No mutations were observed in the baseline plasma samples, in agreement with the TP53 wild-type status observed in baseline tumour samples, indicating that TP53 mutations emerge after the initiation of SAR405838 treatment (posterior predictive probability, P=0.0017).